Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

NADOM : Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

18+Age Over 18

Head and Neck<br/>CancersCancer LocationHead and Neck
Cancers

Systemic therapy,Treatment | Head and neckMelanoma (Ocular)

Trial Overview Read MoreRead more

This phase II study is evaluating how effective targeted therapy (darovasertib) is people with occular (uveal) melanoma who are planned to undergo surgery.
 

This trial is treating patients with occular melanoma (uveal).

This is a systemic therapy trial.

You may be able to join this trial if:

  • You are able to swallow medication by mouth.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma

Other Non-Commercial Sponsor

Anthony Joshua, FRACP

Summary

Eligible participants will undergo up to 4 weeks of treatment with Darovasertib (300mg, twice a day as a starting dose) after fulfilling inclusion/exclusion criteria and consent. Select participants will undergo adjuvant treatment for 6 months based on their initial response.

Recruiting Hospitals Read MoreRead more

Alfred Hospital, Medical Oncology
Prahran
Mr Yijia Chen
yij.chen@alfred.org.au
03 9076 7465

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next